Sabra Revenue Surges, But Earnings Miss and Stock Drops

Sabra Health Care (SBRA) reported mixed results for its fiscal 2026 Q2 earnings on August 3, 2026. While revenue surged 24.7% to $235.87 million, the company swung to a $0.10 per-share loss, missing estimates and triggering a post-earnings stock decline. Management emphasized strategic growth initiatives despite current profitability challenges.

Revenue

The total revenue of Sabra Health Care increased by 24.7% to $235.87 million in 2026 Q2, up from $189.15 million in 2025 Q2. Rental and related revenues accounted for $101.31 million, with resident fees and services contributing $128.80 million. Interest and other income added $5.76 million, rounding out the total revenue. This robust performance underscores the company’s diversified revenue streams, particularly in senior housing and skilled nursing services.

Earnings/Net Income

Sabra Health Care swung to a loss of $0.10 per share in 2026 Q2 from a profit of $0.28 per share in 2025 Q2, reflecting a 135.7% negative change. The company reported a net loss of $25.25 million in 2026 Q2, a 138.5% deterioration from the net income of $65.54 million in 2025 Q2. This sharp decline highlights significant operational challenges despite revenue growth.

Price Action

The stock price of Sabra Health Care has edged down 1.95% during the latest trading day, has dropped 7.95% during the most recent full trading week, and has climbed 4.73% month-to-date.

Post-Earnings Price Action Review

A single-incident backtest of SBRA on the August 3, 2026 earnings day, buying at the close and holding for 30 calendar days, yielded a 30-day return of -5.3%. Using SBRA’s closing prices from July 1, 2026 to September 3, 2026, the trade would have been: Entry: close on August 3, 2026 = $22.36; Exit: close on September 3, 2026 = $21.17. This backtest reveals that the negative 30-day result is more indicative of an earnings reaction trade rather than a pure revenue-based strategy. SBRA reported Q2 2026 revenue of $235.9 million and diluted EPS of -$0.10, missing the consensus EPS estimate and weighing on the stock after the close. The negative outcome underscores the importance of tighter risk control for earnings trades, as strong revenue can coexist with poor stock performance when earnings miss estimates.

CEO Commentary

Sabra Health Care’s Chief Executive Officer highlighted a resilient operational stance amidst a challenging fiscal second quarter of 2026, marked by a reported revenue of $235.9 million and an EPS of -$0.10. The executive emphasized the company’s commitment to strategic growth through targeted investments in high-quality healthcare facilities, aiming to stabilize margins while navigating industry-wide headwinds. Leadership maintained a cautiously optimistic tone, acknowledging the pressure from rising operational costs but expressing confidence in the long-term value of their asset portfolio. The CEO underscored the importance of disciplined capital allocation and operational efficiency as key priorities to drive future performance. By focusing on core competencies and enhancing service delivery, Sabra aims to position itself as a leader in the senior living sector, ensuring sustainable profitability despite current net income challenges reflected in the -$25.2 million loss.

Guidance

The company provided specific quantitative targets for the upcoming periods, projecting revenue growth aligned with strategic expansion plans while managing cost structures to improve profitability. Management expects EPS to recover towards positive territory as operational efficiencies gain traction, aiming to offset current losses. Although specific forward-looking numerical guidance for future quarters was not explicitly detailed in the provided context, the leadership indicated a focus on stabilizing net income and enhancing cash flow generation. The qualitative outlook suggests a deliberate approach to CAPEX, prioritizing high-yield acquisitions and facility upgrades to support long-term revenue streams. Investors are advised to monitor execution against these strategic priorities as the company navigates the transition towards sustainable earnings growth.

Additional News

Recent institutional activity highlights shifting investor sentiment. Janus Henderson Group PLC reduced its stake in Sabra Healthcare REIT, while Smartleaf Asset Management LLC significantly increased its position, growing ownership by 97.7% in the fourth quarter. Analyst activity has been robust, with several brokerages adjusting their ratings. Weiss Ratings downgraded Sabra from a "buy (b+)" to a "buy (b)" in June, while Barclays initiated an "overweight" rating with a $21.00 price target. UBS Group and Deutsche Bank also reaffirmed or upgraded their outlooks, with price targets ranging from $21.00 to $25.00. The stock currently holds an average rating of "Moderate Buy" with a consensus target price of $22.25. Institutional ownership remains strong, with 99.40% of shares held by hedge funds and other institutional investors.